ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa reported a Q1 2026 net loss of $1.8 million, an improvement from $2.3 million in the prior year, driven by a 78% drop in R&D spending due to a paused study and executive retirement. The company ended the quarter with $0.3 million in cash, stating it is only sufficient to fund operations on a month-to-month basis and requires immediate additional financing.
Key figures
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 1793381
- Ga expenses
- 1247077
- Rd expenses
- 57621
- Cash balance
- 302660
- Net loss yoy change
- -$0.5 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.